JP2001521020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001521020A5 JP2001521020A5 JP2000517936A JP2000517936A JP2001521020A5 JP 2001521020 A5 JP2001521020 A5 JP 2001521020A5 JP 2000517936 A JP2000517936 A JP 2000517936A JP 2000517936 A JP2000517936 A JP 2000517936A JP 2001521020 A5 JP2001521020 A5 JP 2001521020A5
- Authority
- JP
- Japan
- Prior art keywords
- acetic acid
- aminomethyl
- cyclopentyl
- methyl
- cyclobutyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 166
- 150000001875 compounds Chemical class 0.000 description 21
- CNCRBAYWBZGPBZ-HTQZYQBOSA-N (7R,8R)-7,8-dimethyl-2-azaspiro[4.4]nonan-3-one Chemical compound C1[C@@H](C)[C@H](C)CC11CC(=O)NC1 CNCRBAYWBZGPBZ-HTQZYQBOSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- WVFKRUXAEOXLHW-HTQZYQBOSA-N 2-[(3R,4R)-3,4-dimethyl-1-(nitromethyl)cyclopentyl]acetic acid Chemical compound C[C@@H]1CC(CC(O)=O)(C[N+]([O-])=O)C[C@H]1C WVFKRUXAEOXLHW-HTQZYQBOSA-N 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- OVCCKUOTVGFWJQ-UHFFFAOYSA-N ethyl 2-(3-benzylcyclobutylidene)acetate Chemical compound C1C(=CC(=O)OCC)CC1CC1=CC=CC=C1 OVCCKUOTVGFWJQ-UHFFFAOYSA-N 0.000 description 2
- XFBFXEQNMLQECT-NXEZZACHSA-N ethyl 2-[(3R,4R)-3,4-dimethyl-1-(nitromethyl)cyclopentyl]acetate Chemical compound CCOC(=O)CC1(C[N+]([O-])=O)C[C@@H](C)[C@H](C)C1 XFBFXEQNMLQECT-NXEZZACHSA-N 0.000 description 2
- QLHNVWKVWDIVIG-RKDXNWHRSA-N ethyl 2-[(3R,4R)-3,4-dimethylcyclopentylidene]acetate Chemical compound CCOC(=O)C=C1C[C@@H](C)[C@H](C)C1 QLHNVWKVWDIVIG-RKDXNWHRSA-N 0.000 description 2
- QLHNVWKVWDIVIG-DTORHVGOSA-N ethyl 2-[(3R,4S)-3,4-dimethylcyclopentylidene]acetate Chemical compound CCOC(=O)C=C1C[C@H](C)[C@H](C)C1 QLHNVWKVWDIVIG-DTORHVGOSA-N 0.000 description 2
- UDBYYPDEHJNWBE-UHFFFAOYSA-N ethyl 2-[1-(nitromethyl)cyclobutyl]acetate Chemical compound CCOC(=O)CC1(C[N+]([O-])=O)CCC1 UDBYYPDEHJNWBE-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- -1 hydroxy, hydroxymethyl Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- OPAXRDNEIABTQI-VIFPVBQESA-N 2-[(1R)-1-(aminomethyl)-2,2-dimethylcyclobutyl]acetic acid Chemical compound CC1(C)CC[C@@]1(CN)CC(O)=O OPAXRDNEIABTQI-VIFPVBQESA-N 0.000 description 1
- DNHPJOLWCOXHOV-JTQLQIEISA-N 2-[(1R)-1-(aminomethyl)-2,2-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CCC[C@@]1(CN)CC(O)=O DNHPJOLWCOXHOV-JTQLQIEISA-N 0.000 description 1
- SIKUEILNNOXUAZ-LBPRGKRZSA-N 2-[(1R)-1-(aminomethyl)-3,3-diethylcyclopentyl]acetic acid Chemical compound CCC1(CC)CC[C@](CN)(CC(O)=O)C1 SIKUEILNNOXUAZ-LBPRGKRZSA-N 0.000 description 1
- QZBKCCCUSMQVTC-JTQLQIEISA-N 2-[(1R)-1-(aminomethyl)-3,3-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CC[C@](CN)(CC(O)=O)C1 QZBKCCCUSMQVTC-JTQLQIEISA-N 0.000 description 1
- OPAXRDNEIABTQI-SECBINFHSA-N 2-[(1S)-1-(aminomethyl)-2,2-dimethylcyclobutyl]acetic acid Chemical compound CC1(C)CC[C@]1(CN)CC(O)=O OPAXRDNEIABTQI-SECBINFHSA-N 0.000 description 1
- DNHPJOLWCOXHOV-SNVBAGLBSA-N 2-[(1S)-1-(aminomethyl)-2,2-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CCC[C@]1(CN)CC(O)=O DNHPJOLWCOXHOV-SNVBAGLBSA-N 0.000 description 1
- SIKUEILNNOXUAZ-GFCCVEGCSA-N 2-[(1S)-1-(aminomethyl)-3,3-diethylcyclopentyl]acetic acid Chemical compound CCC1(CC)CC[C@@](CN)(CC(O)=O)C1 SIKUEILNNOXUAZ-GFCCVEGCSA-N 0.000 description 1
- QZBKCCCUSMQVTC-SNVBAGLBSA-N 2-[(1S)-1-(aminomethyl)-3,3-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CC[C@@](CN)(CC(O)=O)C1 QZBKCCCUSMQVTC-SNVBAGLBSA-N 0.000 description 1
- VVJFYFLGWOCDQD-HTQZYQBOSA-N 2-[(2R,5R)-1-(aminomethyl)-2,5-dimethylcyclopentyl]acetic acid Chemical compound C[C@@H]1CC[C@@H](C)C1(CN)CC(O)=O VVJFYFLGWOCDQD-HTQZYQBOSA-N 0.000 description 1
- VVJFYFLGWOCDQD-YUMQZZPRSA-N 2-[(2S,5S)-1-(aminomethyl)-2,5-dimethylcyclopentyl]acetic acid Chemical compound C[C@H]1CC[C@H](C)C1(CN)CC(O)=O VVJFYFLGWOCDQD-YUMQZZPRSA-N 0.000 description 1
- FKLQZOOZJOUECB-VXGBXAGGSA-N 2-[(3R,4R)-1-(aminomethyl)-3,4-di(propan-2-yl)cyclopentyl]acetic acid Chemical compound CC(C)[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C(C)C FKLQZOOZJOUECB-VXGBXAGGSA-N 0.000 description 1
- HBFZWKRCDVWGSA-WOJBJXKFSA-N 2-[(3R,4R)-1-(aminomethyl)-3,4-dibenzylcyclopentyl]acetic acid Chemical compound C([C@@H]1CC(C[C@H]1CC=1C=CC=CC=1)(CC(O)=O)CN)C1=CC=CC=C1 HBFZWKRCDVWGSA-WOJBJXKFSA-N 0.000 description 1
- KOPGUPUTANQKJY-NXEZZACHSA-N 2-[(3R,4R)-1-(aminomethyl)-3,4-diethylcyclopentyl]acetic acid Chemical compound CC[C@@H]1CC(CN)(CC(O)=O)C[C@H]1CC KOPGUPUTANQKJY-NXEZZACHSA-N 0.000 description 1
- IUVMAUQEZFTTFB-HTQZYQBOSA-N 2-[(3R,4R)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid Chemical compound C[C@@H]1CC(CN)(CC(O)=O)C[C@H]1C IUVMAUQEZFTTFB-HTQZYQBOSA-N 0.000 description 1
- MJEPQHYIBKJJGY-SCLLHFNJSA-N 2-[(3R,4R)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid;hydrochloride Chemical compound Cl.C[C@@H]1CC(CN)(CC(O)=O)C[C@H]1C MJEPQHYIBKJJGY-SCLLHFNJSA-N 0.000 description 1
- BHQDRZBQUNHTBG-ROUUACIJSA-N 2-[(3R,4R)-1-(aminomethyl)-3,4-diphenylcyclopentyl]acetic acid Chemical compound C1([C@H]2[C@@H](CC(C2)(CC(O)=O)CN)C=2C=CC=CC=2)=CC=CC=C1 BHQDRZBQUNHTBG-ROUUACIJSA-N 0.000 description 1
- DPSPUVHOQGLSSE-VXGBXAGGSA-N 2-[(3R,4R)-1-(aminomethyl)-3,4-ditert-butylcyclopentyl]acetic acid Chemical compound CC(C)(C)[C@@H]1CC(CN)(CC(O)=O)C[C@H]1C(C)(C)C DPSPUVHOQGLSSE-VXGBXAGGSA-N 0.000 description 1
- FKLQZOOZJOUECB-RYUDHWBXSA-N 2-[(3S,4S)-1-(aminomethyl)-3,4-di(propan-2-yl)cyclopentyl]acetic acid Chemical compound CC(C)[C@@H]1CC(CN)(CC(O)=O)C[C@H]1C(C)C FKLQZOOZJOUECB-RYUDHWBXSA-N 0.000 description 1
- HBFZWKRCDVWGSA-PMACEKPBSA-N 2-[(3S,4S)-1-(aminomethyl)-3,4-dibenzylcyclopentyl]acetic acid Chemical compound C([C@H]1CC(C[C@@H]1CC=1C=CC=CC=1)(CC(O)=O)CN)C1=CC=CC=C1 HBFZWKRCDVWGSA-PMACEKPBSA-N 0.000 description 1
- KOPGUPUTANQKJY-UWVGGRQHSA-N 2-[(3S,4S)-1-(aminomethyl)-3,4-diethylcyclopentyl]acetic acid Chemical compound CC[C@H]1CC(CN)(CC(O)=O)C[C@@H]1CC KOPGUPUTANQKJY-UWVGGRQHSA-N 0.000 description 1
- BHQDRZBQUNHTBG-QZTJIDSGSA-N 2-[(3S,4S)-1-(aminomethyl)-3,4-diphenylcyclopentyl]acetic acid Chemical compound C1([C@@H]2[C@H](CC(C2)(CC(O)=O)CN)C=2C=CC=CC=2)=CC=CC=C1 BHQDRZBQUNHTBG-QZTJIDSGSA-N 0.000 description 1
- DPSPUVHOQGLSSE-RYUDHWBXSA-N 2-[(3S,4S)-1-(aminomethyl)-3,4-ditert-butylcyclopentyl]acetic acid Chemical compound CC(C)(C)[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C(C)(C)C DPSPUVHOQGLSSE-RYUDHWBXSA-N 0.000 description 1
- ZKPYVRKWQDIKJF-UHFFFAOYSA-N 2-[1-(aminomethyl)-2,2,3,3,4,4-hexamethylcyclobutyl]acetic acid Chemical compound CC1(C)C(C)(C)C(CN)(CC(O)=O)C1(C)C ZKPYVRKWQDIKJF-UHFFFAOYSA-N 0.000 description 1
- XRAYXEBZNYLCBY-UHFFFAOYSA-N 2-[1-(aminomethyl)-2,2,4,4-tetramethylcyclobutyl]acetic acid Chemical compound CC1(C)CC(C)(C)C1(CN)CC(O)=O XRAYXEBZNYLCBY-UHFFFAOYSA-N 0.000 description 1
- PSOWEDFUUXXEHX-UHFFFAOYSA-N 2-[1-(aminomethyl)-2,2,5,5-tetramethylcyclopentyl]acetic acid Chemical compound CC1(C)CCC(C)(C)C1(CN)CC(O)=O PSOWEDFUUXXEHX-UHFFFAOYSA-N 0.000 description 1
- SEPPWOWOFXDAAP-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3,4,4-tetraethylcyclopentyl]acetic acid Chemical compound CCC1(CC)CC(CN)(CC(O)=O)CC1(CC)CC SEPPWOWOFXDAAP-UHFFFAOYSA-N 0.000 description 1
- FLNCTXNXKXKYGH-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3,4,4-tetramethylcyclopentyl]acetic acid Chemical compound CC1(C)CC(CN)(CC(O)=O)CC1(C)C FLNCTXNXKXKYGH-UHFFFAOYSA-N 0.000 description 1
- UWYKQWDIAKQCEJ-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-di(propan-2-yl)cyclobutyl]acetic acid Chemical compound CC(C)C1(C(C)C)CC(CN)(CC(O)=O)C1 UWYKQWDIAKQCEJ-UHFFFAOYSA-N 0.000 description 1
- SRLZVTNHASZZSM-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dibenzylcyclobutyl]acetic acid Chemical compound C1C(CN)(CC(O)=O)CC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 SRLZVTNHASZZSM-UHFFFAOYSA-N 0.000 description 1
- BSRBEUFYGVVBLO-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-diethylcyclobutyl]acetic acid Chemical compound CCC1(CC)CC(CN)(CC(O)=O)C1 BSRBEUFYGVVBLO-UHFFFAOYSA-N 0.000 description 1
- XEXRZUKGFDRWLE-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dimethylcyclobutyl]acetic acid Chemical compound CC1(C)CC(CN)(CC(O)=O)C1 XEXRZUKGFDRWLE-UHFFFAOYSA-N 0.000 description 1
- LJBMNGNDAMRUJV-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dimethylcyclopentyl]acetic acid;hydrochloride Chemical compound Cl.CC1(C)CCC(CN)(CC(O)=O)C1 LJBMNGNDAMRUJV-UHFFFAOYSA-N 0.000 description 1
- FUDBUFIPBPLPHY-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-diphenylcyclobutyl]acetic acid Chemical compound C1C(CN)(CC(O)=O)CC1(C=1C=CC=CC=1)C1=CC=CC=C1 FUDBUFIPBPLPHY-UHFFFAOYSA-N 0.000 description 1
- CYOHDPOYWOPSRK-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-ditert-butylcyclobutyl]acetic acid Chemical compound CC(C)(C)C1(C(C)(C)C)CC(CN)(CC(O)=O)C1 CYOHDPOYWOPSRK-UHFFFAOYSA-N 0.000 description 1
- UKPVCXAEJOKSRI-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclobutyl]acetic acid;hydrochloride Chemical compound Cl.OC(=O)CC1(CN)CCC1 UKPVCXAEJOKSRI-UHFFFAOYSA-N 0.000 description 1
- RDJWDZURNKBDSS-UHFFFAOYSA-N 8,8-dimethyl-2-azaspiro[4.4]nonan-3-one Chemical compound C1C(C)(C)CCC11CC(=O)NC1 RDJWDZURNKBDSS-UHFFFAOYSA-N 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- IUVMAUQEZFTTFB-YUMQZZPRSA-N Atagabalin Chemical compound C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C IUVMAUQEZFTTFB-YUMQZZPRSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 206010042772 Syncope Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 201000002146 gastrointestinal system disease Diseases 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 230000003483 hypokinetic Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 230000002981 neuropathic Effects 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6364497P | 1997-10-27 | 1997-10-27 | |
US60/063,644 | 1997-10-27 | ||
US9768598P | 1998-08-24 | 1998-08-24 | |
US60/097,685 | 1998-08-24 | ||
PCT/US1998/019876 WO1999021824A1 (en) | 1997-10-27 | 1998-09-23 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005319009A Division JP4263717B2 (ja) | 1997-10-27 | 2005-11-02 | 医薬として有用な環状アミノ酸およびその誘導体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001521020A JP2001521020A (ja) | 2001-11-06 |
JP2001521020A5 true JP2001521020A5 (pt) | 2006-01-05 |
JP3756761B2 JP3756761B2 (ja) | 2006-03-15 |
Family
ID=26743626
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000517936A Expired - Fee Related JP3756761B2 (ja) | 1997-10-27 | 1998-09-23 | 医薬として有用な環状アミノ酸およびその誘導体 |
JP2005319009A Expired - Fee Related JP4263717B2 (ja) | 1997-10-27 | 2005-11-02 | 医薬として有用な環状アミノ酸およびその誘導体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005319009A Expired - Fee Related JP4263717B2 (ja) | 1997-10-27 | 2005-11-02 | 医薬として有用な環状アミノ酸およびその誘導体 |
Country Status (31)
Country | Link |
---|---|
US (3) | US6635673B1 (pt) |
EP (1) | EP1032555B1 (pt) |
JP (2) | JP3756761B2 (pt) |
KR (1) | KR100589066B1 (pt) |
CN (2) | CN1303059C (pt) |
AR (1) | AR013726A1 (pt) |
AT (1) | ATE323067T1 (pt) |
AU (1) | AU755800B2 (pt) |
BR (1) | BR9813284B1 (pt) |
CA (1) | CA2303244C (pt) |
CO (1) | CO5280097A1 (pt) |
CU (1) | CU23048A3 (pt) |
CY (1) | CY1105062T1 (pt) |
DE (1) | DE69834204T2 (pt) |
DK (1) | DK1032555T3 (pt) |
ES (1) | ES2260850T3 (pt) |
GE (1) | GEP20094817B (pt) |
HK (2) | HK1030768A1 (pt) |
HU (1) | HUP0004310A3 (pt) |
IL (1) | IL134732A (pt) |
IS (1) | IS2489B (pt) |
NO (1) | NO327671B1 (pt) |
NZ (1) | NZ503651A (pt) |
PE (1) | PE122799A1 (pt) |
PL (2) | PL199794B1 (pt) |
PT (1) | PT1032555E (pt) |
SI (1) | SI1032555T1 (pt) |
TR (1) | TR200001170T2 (pt) |
UY (1) | UY25223A1 (pt) |
WO (1) | WO1999021824A1 (pt) |
ZA (1) | ZA989740B (pt) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU225502B1 (en) * | 1998-12-29 | 2007-01-29 | Richter Gedeon Vegyeszet | Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates |
PT1180094E (pt) * | 1999-05-26 | 2004-10-29 | Warner Lambert Co | Aminoacidos policiclicos fundidos como agentes farmaceuticos |
OA11962A (en) * | 1999-06-10 | 2006-04-17 | Warner Lambert Co | Mono-and disubstituted 3-propyl gamma-aminobutyricacids. |
US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
EP1840117A1 (en) * | 1999-06-10 | 2007-10-03 | Warner-Lambert Company LLC | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
US6642398B2 (en) | 1999-06-10 | 2003-11-04 | Warner-Lambert Company | Mono-and disubstituted 3-propyl gamma-aminobutyric acids |
HN2000000224A (es) | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
HUP0203812A3 (en) * | 1999-12-08 | 2004-12-28 | Warner Lambert Co | Method for the stereoselective synthesis of cyclic amino acids |
US6864390B2 (en) | 1999-12-08 | 2005-03-08 | Warner-Lambert Company | Method for the stereoselective synthesis of cyclic amino acids |
GB2362646A (en) * | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
MXPA02010668A (es) | 2000-06-26 | 2003-03-10 | Warner Lambert Co | Analogos de gabapentina para alteraciones del sueno. |
GB2364049A (en) * | 2000-06-28 | 2002-01-16 | Warner Lambert Co | Cyclic ketones and their use in the synthesis of amino acids |
AU2002230398A1 (en) | 2000-10-06 | 2002-04-29 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
AU2002211863A1 (en) | 2000-10-06 | 2002-04-15 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
EP1226820A1 (en) * | 2001-01-26 | 2002-07-31 | Warner-Lambert Company | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders |
EA006396B1 (ru) * | 2001-04-19 | 2005-12-29 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си | Конденсированные бициклические аминокислоты |
GB2374595A (en) * | 2001-04-19 | 2002-10-23 | Warner Lambert Co | Fused bicyclic or tricyclic amino acids |
US7420002B2 (en) | 2001-06-11 | 2008-09-02 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
KR20040016882A (ko) | 2001-06-11 | 2004-02-25 | 제노포트 인코포레이티드 | 감소된 독성을 가진 gaba 유사체 프로드러그의 구강투여용 투여 형태물 |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) * | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
WO2003077902A1 (en) | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
US7026351B2 (en) | 2002-03-20 | 2006-04-11 | Xenoport, Inc. | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof |
AU2003243180A1 (en) | 2002-05-17 | 2003-12-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US7018818B2 (en) | 2002-10-04 | 2006-03-28 | Pfizer Inc. | Intermediates in the preparation of therapeutic fused bicyclic amino acids |
GB0223072D0 (en) * | 2002-10-04 | 2002-11-13 | Pfizer Ltd | Cyclic nitromethyl acetic acid derivatives |
US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
US7060727B2 (en) | 2002-12-11 | 2006-06-13 | Xenoport, Inc. | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof |
EP1572184A1 (en) * | 2002-12-13 | 2005-09-14 | Warner-Lambert Company | Gabapentin analogues for fibromyalgia and other related disorders |
WO2004054566A1 (en) | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
RU2331438C2 (ru) | 2002-12-13 | 2008-08-20 | Уорнер-Ламберт Компани Ллс | Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей |
WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
WO2005025562A1 (en) | 2003-09-11 | 2005-03-24 | Xenoport, Inc. | Treating and/or preventing urinary incontinence using prodrugs of gaba analogs |
NZ545494A (en) | 2003-09-12 | 2009-10-30 | Pfizer | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
SG146643A1 (en) | 2003-09-17 | 2008-10-30 | Xenoport Inc | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
DK1677767T3 (da) | 2003-10-14 | 2011-10-24 | Xenoport Inc | Krystallinsk form af gamma-aminobutyrsyre-analog |
AU2004305563C1 (en) | 2003-12-11 | 2011-07-07 | Sunovion Pharmaceuticals Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
UA82292C2 (uk) * | 2004-04-14 | 2008-03-25 | Пфайзер Продактс Инк. | Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти) |
EP1811986B1 (en) | 2004-11-04 | 2014-03-26 | XenoPort, Inc. | Gabapentin prodrug sustained release oral dosage forms |
WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
EP1912936A2 (en) * | 2005-07-18 | 2008-04-23 | Pharmacia & Upjohn Company LLC | Stereoselective synthesis of 3,4-disubstituted cyclopentanones and related compounds |
EP1820502A1 (en) | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
MX2008011396A (es) * | 2006-03-06 | 2008-09-18 | Pfizer Prod Inc | Ligandos alfa-2-delta para sueño no reconstituyente. |
AR061728A1 (es) * | 2006-06-30 | 2008-09-17 | Pfizer Prod Inc | Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1 |
WO2008077599A1 (en) | 2006-12-22 | 2008-07-03 | Recordati Ireland Limited | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS |
WO2008155619A2 (en) * | 2007-06-21 | 2008-12-24 | Pfizer Inc. | Preparation of optically-active cyclic amino acids |
RU2446148C2 (ru) | 2007-09-28 | 2012-03-27 | Дайити Санкио Компани, Лимитед | Бициклическое производное гамма-аминокислоты |
WO2009094563A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use |
WO2009094569A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Method for the enzymatic kinetic resolution of acyloxyalkyl thiocarbonates used for the synthesis of acyloxyalkyl carbamates |
WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
ES2589915T3 (es) | 2008-10-08 | 2016-11-17 | Xgene Pharmaceutical Inc | Conjugados de GABA y métodos de utilización de los mismos |
CA2756750C (en) | 2009-03-26 | 2014-05-13 | Daiichi Sankyo Company, Limited | A method for producing bicyclic .gamma.-amino acid derivative |
EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
JP5922118B2 (ja) | 2011-06-08 | 2016-05-24 | 第一三共株式会社 | イミニウム塩を経由する二環性化合物の製造方法 |
WO2012169475A1 (ja) | 2011-06-08 | 2012-12-13 | 第一三共株式会社 | クライゼン転位反応による二環性化合物の製造方法 |
CA2859003C (en) | 2011-12-15 | 2016-11-01 | Daiichi Sankyo Company, Limited | Optical resolution method for bicyclic compound using asymmetric catalyst |
IN2014DN07923A (pt) | 2012-04-10 | 2015-05-01 | Daiichi Sankyo Companyltd | |
US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
HUE047629T2 (hu) | 2013-01-28 | 2020-05-28 | Lopez Hector L | Eljárások ß-alanin tolerancia, farmakodinamika és hatékonyság javítására és azok alkalmazása |
TWI635071B (zh) | 2013-07-08 | 2018-09-11 | 第一三共股份有限公司 | 光學活性二環γ-胺基酸衍生物及其製造方法 |
US20160310501A1 (en) | 2013-12-17 | 2016-10-27 | Laboratorios Del Dr. Esteve, S.A. | Gabapentinoids and sigma receptor ligands combinations |
AU2014364647A1 (en) | 2013-12-17 | 2016-06-23 | Laboratorios Del Dr. Esteve, S.A. | Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations |
BR112020022885A2 (pt) | 2018-05-14 | 2021-03-23 | Xgene Pharmaceutical Inc. | formas cristalinas de conjugados de fármacos de carbamato de 1-(aciloxi)-alquila de naproxeno e pregabalina |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
DE2611690A1 (de) | 1976-03-19 | 1977-09-22 | Goedecke Ag | Cyclische sulfonyloxyimide |
CA1085420A (en) | 1977-03-24 | 1980-09-09 | Johannes Hartenstein | 1-aminomethyl-1-cycloalkane-acetic acid |
DE3928184A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte |
US5132451A (en) | 1989-08-25 | 1992-07-21 | Warner-Lambert Company | Process for cyclic amino acid anticonvulsant compounds |
US5319135A (en) | 1989-08-25 | 1994-06-07 | Warner-Lambert Company | Process for cyclic amino acid anticonvulsant compounds |
US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
EP0458751A1 (en) | 1990-05-25 | 1991-11-27 | Warner-Lambert Company | Delivery system for cyclic amino acids with improved taste, texture and compressibility |
US5025035A (en) | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
EP0482834B1 (en) | 1990-10-20 | 1996-01-17 | Takasago International Corporation | Process for producing alpha-hydroxyketones |
CA2120351A1 (en) | 1991-10-02 | 1993-04-15 | Siegfried B. Christensen, Iv | Cyclopentane and cyclopentene derivatives with antiallergic antiinflammatory and tumor necrosis factor inhibiting activity |
US5631291A (en) | 1992-05-29 | 1997-05-20 | Bayer Aktiengesellschaft | Cyclopentane- and -pentene-β-amino acids |
DE4400749A1 (de) | 1994-01-13 | 1995-07-20 | Bayer Ag | Neues hochenantioselektives Verfahren zur Herstellung von enantiomerenreinen Cyclopentan- und -penten-beta-Aminosäuren |
CZ291757B6 (cs) | 1994-07-27 | 2003-05-14 | Warner-Lambert Company | Léčivo pro léčení úzkosti a panického strachu |
US5510381A (en) | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
DK0888285T3 (da) * | 1996-03-14 | 2002-04-08 | Warner Lambert Co | Nye broforbundne cycliske aminosyrer som farmaceutiske midler |
HRP980342A2 (en) | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
US9858641B2 (en) * | 2014-12-15 | 2018-01-02 | International Business Machines Corporation | Representing a system using viewpoints |
US9419648B1 (en) * | 2015-09-18 | 2016-08-16 | Intel Corporation | Supporting data compression using match scoring |
-
1998
- 1998-09-23 DE DE69834204T patent/DE69834204T2/de not_active Expired - Lifetime
- 1998-09-23 SI SI9830831T patent/SI1032555T1/sl unknown
- 1998-09-23 KR KR1020007004472A patent/KR100589066B1/ko not_active IP Right Cessation
- 1998-09-23 DK DK98950649T patent/DK1032555T3/da active
- 1998-09-23 TR TR2000/01170T patent/TR200001170T2/xx unknown
- 1998-09-23 IL IL13473298A patent/IL134732A/en not_active IP Right Cessation
- 1998-09-23 CU CU20000089A patent/CU23048A3/es not_active IP Right Cessation
- 1998-09-23 GE GEAP199811187A patent/GEP20094817B/en unknown
- 1998-09-23 CN CNB2003101209321A patent/CN1303059C/zh not_active Expired - Fee Related
- 1998-09-23 AU AU96638/98A patent/AU755800B2/en not_active Ceased
- 1998-09-23 PL PL380277A patent/PL199794B1/pl not_active IP Right Cessation
- 1998-09-23 PL PL340285A patent/PL199500B1/pl not_active IP Right Cessation
- 1998-09-23 CN CNB98810346XA patent/CN1138755C/zh not_active Expired - Fee Related
- 1998-09-23 CA CA002303244A patent/CA2303244C/en not_active Expired - Fee Related
- 1998-09-23 WO PCT/US1998/019876 patent/WO1999021824A1/en active IP Right Grant
- 1998-09-23 EP EP98950649A patent/EP1032555B1/en not_active Expired - Lifetime
- 1998-09-23 AT AT98950649T patent/ATE323067T1/de active
- 1998-09-23 PT PT98950649T patent/PT1032555E/pt unknown
- 1998-09-23 NZ NZ503651A patent/NZ503651A/xx not_active IP Right Cessation
- 1998-09-23 ES ES98950649T patent/ES2260850T3/es not_active Expired - Lifetime
- 1998-09-23 US US09/485,382 patent/US6635673B1/en not_active Expired - Fee Related
- 1998-09-23 BR BRPI9813284-9A patent/BR9813284B1/pt not_active IP Right Cessation
- 1998-09-23 JP JP2000517936A patent/JP3756761B2/ja not_active Expired - Fee Related
- 1998-09-23 HU HU0004310A patent/HUP0004310A3/hu unknown
- 1998-10-26 UY UY25223A patent/UY25223A1/es not_active IP Right Cessation
- 1998-10-26 ZA ZA989740A patent/ZA989740B/xx unknown
- 1998-10-26 CO CO98062354A patent/CO5280097A1/es not_active Application Discontinuation
- 1998-10-26 AR ARP980105348A patent/AR013726A1/es active IP Right Grant
- 1998-10-27 PE PE1998001007A patent/PE122799A1/es not_active Application Discontinuation
-
2000
- 2000-03-03 IS IS5395A patent/IS2489B/is unknown
- 2000-04-26 NO NO20002118A patent/NO327671B1/no not_active IP Right Cessation
-
2001
- 2001-03-12 HK HK01101728A patent/HK1030768A1/xx not_active IP Right Cessation
-
2003
- 2003-05-30 US US10/448,834 patent/US6921835B2/en not_active Expired - Fee Related
-
2004
- 2004-07-06 HK HK04104849A patent/HK1061841A1/xx not_active IP Right Cessation
-
2005
- 2005-03-11 US US11/078,961 patent/US7122678B2/en not_active Expired - Fee Related
- 2005-11-02 JP JP2005319009A patent/JP4263717B2/ja not_active Expired - Fee Related
-
2006
- 2006-07-03 CY CY20061100906T patent/CY1105062T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001521020A5 (pt) | ||
EP0641330B1 (en) | Gaba and l-glutamic acid analogs for antiseizure treatment | |
EP0082088B1 (fr) | Nouveaux dérivés d'aminoacides, et leur application thérapeutique | |
US6262120B1 (en) | GABA and L-glutamic acid analogs for antiseizure treatment | |
KR100694735B1 (ko) | 일치환 및 이치환된 3-프로필 감마-아미노부티르산 | |
EP0318377A2 (fr) | Nouveaux composés énantiomères dérivés d'amino-acides, leur procédé de préparation et leurs applications thérapeutiques | |
JP2006515587A5 (pt) | ||
EP1009750B1 (fr) | Nouveaux derives d'(alpha-aminophosphino)peptides, leur procede de preparation et leurs applications therapeutiques | |
EP0362001B1 (fr) | N-cycloalkylalkyle benzylamines alpha,alpha disubstituées, leur procédé de préparation, leur utilisation comme médicament et leurs intermédiaires de synthèse | |
EP0639586B1 (fr) | Dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
JP3576193B2 (ja) | ビフェニルメチル置換バレリルアミド誘導体 | |
EP0262053A2 (fr) | Nouveaux dérivés d'amino-acides, leur procédé de préparation et compositions pharmaceutiques les contenant | |
JP3084345B2 (ja) | 光学活性な2−プロピルオクタン酸の製造方法 | |
EP2188244A2 (en) | Novel method for preparing pregabalin | |
JPH02233650A (ja) | 新規なテトラリン誘導体 | |
JP2778103B2 (ja) | 光学活性なスレオージヒドロキシフェニルセリン誘導体の製造方法 | |
IE56654B1 (en) | A process for the resolution of racemates of optically active bicyclic imino-alpha-carboxylic esters,and the use of the compounds thus obtainable for the synthesis of carboxyalkyldipeptides | |
EP1073664B1 (fr) | Derives d'(alpha-aminophosphino) peptides et compositions les contenant | |
Detterbeck et al. | Synthesis and structure elucidation of open-chained putrescine-bisamides from Aglaia species | |
KR100225829B1 (ko) | 라세미성 1,2,3,4-테트라하이드로이소퀴놀린-3-카복실산 및 광학 활성 1,2,3,4-테트라하이드로이소퀴놀린-3-카복실산의 제조방법 | |
EP0869952B1 (fr) | Derives de 5-naphtalen-1-y1-1,3-dioxanes, leur preparation et leur application en therapeutique | |
FR2602511A1 (fr) | Peptides et derives peptidiques, leur preparation et leur utilisation comme medicaments | |
EP0347313B1 (fr) | Ethers de la 2-amino-7-hydroxytétraline | |
Fukuari et al. | Asymmetric synthesis of D-(E)-2-amino-5-phosphono-3-pentenoic acid (APPA) by using a chiral auxiliary | |
CA2261843A1 (fr) | Derives du thienylcyclohexane pour la synthese de thienylcyclohexyles |